Preparation and evaluation of antisera directed against cancer specific moiety of antigenic determinants on carcinoembryonic antigen

Matsuoka, Yoshikazu; Tsuru, Eiko; Sawada, Hiroko

doi:10.1016/0019-2791(75)90229-3

Cited by 18 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fact that CEA is a large molecule (Kupchik et al 1973), is heterogenous (Gold et al 1973), and possesses several different carbohydrates (Banjo et al 1974) raises the possibility that multiple antigenic determinants may be present on the molecule. Matsuoka et al (1975) showed a unique determinant in the CEA molecule which was detectable by specially prepared guinea pig anti-CEA antisera in almost all CEA preparations from tumor tissues, and designated it tentatively as cancer determinant. Kuroki et al (1981) reported that CEA molecule possessed cancer specific antigenic determinants and the antigenic determinants cross-reactive with antigens which are extractable from feces of normal adults.…”

Section: Resultsmentioning

confidence: 97%

A monoclonal antibody against human colon cancers.

Kotanagi

Takahashi

Masuko

et al. 1986

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 97%

A monoclonal antibody against human colon cancers.

Kotanagi

Takahashi

Masuko

et al. 1986

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Carcinoembryonic antigen (CEA) in clinical medicine.Historical perspectives, pitfalls and projections

Gold

Shuster

Freedman

1978

Cancer

View full text Add to dashboard Cite

Carcinoembryonic antigen (CEA) was first detected by the immunization of rabbits with human colon cancer extract. The techniques of antiserum absorption and immunologic tolerance were employed in an attempt to render the resulting antisera tumor-specific. Using the procedures of precipitation and precipitin-inhibition in gel media, hemagglutination, passive cutaneous anaphylaxis and immunofluorescence, CEA was identified exclusively in all cancers of gastrointestinal origin and fetal digestive organs in the first two trimesters of gestation. The subsequent development of radioimmunoassays for CEA has raised the question of the presence of this material, in very low concentrations, in other normal and diseased (cancerous and noncancerous) tissue, but the problem of cross-reactivity within a family of closely related, but nonidentical, molecules remains to be resolved. CEA was initially purified by a sequence of steps involving extraction in perchloric acid, sieve chromatography, and preparative block electrophoresis. The molecule was characterized as a relatively heterogeneous acid glycoprotein with a molecular weight of approximately 200,000 and its carbohydrate (one-half to two-thirds of the molecule) and protein composition were determined. CEA was localized to the glycocalyx of the colon cancer cell and it was found that the CEA could be released from this site into the circulation of the cancer patient, where it could then be detected by means of radioimmunoassay. The clinical implications of this observation, as they have evolved over the past eight years, form the basis of the papers that constitute this supplement.

show abstract

Proteolytic release of antigenic fragments corresponding to normal fecal antigen and non‐specific cross‐reacting antigen from carcinoembryonic antigen

Matsuoka

Koga

Maruta

et al. 1978

Intl Journal of Cancer

View full text Add to dashboard Cite

Three immunogenic parts have so far been identified in the carcinoembryonic antigen (CEA) molecule. These are: determinants cross-reactint with the normal fecal antigen (NFA) (NFA determinant); determinants cross-reacting antigen (NCA) (NCA determinant); and determinants which appear to be more cancer-specific (cancer determinant). The chemical nature of these parts of the CEA molecule was investigated by digestion with proteolytic enzymes together with anti-CEA preparations with which these three immunogenic parts of CEA molecule could be identified. The CEA digest obtained with pepsin did not react in immunodiffusion and radioimmunoassay, indicating that pepsin completely destroyed all the antigenic parts. Digestion by pronase E destroyed only the cancer determinant and liberated two antigenic fragments corresponding to the NFA determinant and the NCA determinant, respectively. These results suggest that the cancer determinant may reside in a protein or a peptide part of the molecule. The chemical nature of the NFA and NCA determinant remains to be clarified.

show abstract

Preparation and evaluation of antisera directed against cancer specific moiety of antigenic determinants on carcinoembryonic antigen

Cited by 18 publications

References 8 publications

A monoclonal antibody against human colon cancers.

A monoclonal antibody against human colon cancers.

Carcinoembryonic antigen (CEA) in clinical medicine.Historical perspectives, pitfalls and projections

Proteolytic release of antigenic fragments corresponding to normal fecal antigen and non‐specific cross‐reacting antigen from carcinoembryonic antigen

Contact Info

Product

Resources

About